Create a free Healthcare Packaging account to continue reading

Through the Line Podcast: Why the NDC-12 Deadline is a Hard Stop for Pharma Packaging Lines

What happens to a pharma packaging line when the industry runs out of 10-digit drug codes?

Listen in to hear why the FDA’s move to a 12-digit National Drug Code by 2033 can’t be extended, and how the denser 2D barcodes it may require can strain printers, vision systems, and line software. The episode covers why packaging, IT, regulatory, and finance teams need to start mapping their systems now, how to build NDC-12 requirements into upcoming equipment purchases, and why printing a 12-digit label too early could get a product treated as misbranded.

Follow this podcast on your favorite streaming platform - links can be found by clicking here.

Transcript
Welcome to Through the Line, the podcast exploring innovations and information across the packaging and processing landscape. From topics impacting consumer packaged goods and healthcare packaging to the latest technologies in food processing operations.
 
Hi, Liz Cuneo here, editor-in-chief of healthcare packaging. What follows is an AI-generated podcast from a recent article that I wrote on our website all about the NDC 12 transition. Learn why the transition has a strict 2033 deadline and what companies need to do and know before the deadline comes.
 
This deep dive explores the pharmaceutical industry's mandatory transition to the 12-digit national drug code by 2033, unpacking why packaging and processing professionals must begin overhauling their systems, equipment, and budgets immediately to avoid operational paralysis.
 
Yeah, that is the exact reality we are looking at today.
 
So just to set the stage, imagine walking onto your packaging floor in, say, 2033. You have this brand new multi-million dollar blister line, and it's running perfectly. The motors are humming, cartons are folding, and then suddenly the entire line just stops.
 
Just completely dead in the water.
 
Exactly. Software throws a fatal error, the vision system starts rejecting every single package right into the scrap bin. Your overall equipment effectiveness just drops to zero.
 
And the crazy part is it's not because a belt snapped or a motor burned out.
 
No, it's simply because your packaging line ran out of numbers. So welcome to the deep dive. If you are a packaging or processing professional working literally anywhere within the pharmaceutical supply chain, this discussion is designed specifically for you. Our mission today is to unpack this really critical piece of industry analysis titled The NDC 12 Deadline is 2033. Hardstop.
 
It's a great title because it really doesn't leave any room for misinterpretation.
 
Aaron Powell We are looking at a regulatory deadline that is, frankly, still seven years away. Yet it's already dominating industry conversations everywhere.
 
And it's a timeline that feels deceivingly far off, especially given the current state of the industry.
 
So for sure, people are exhausted.
 
Exactly. Right now, pharmaceutical manufacturers, logistics providers, packaging engineers, they are all still dealing with this intense fatigue from the Drug Supply Chain Security Act.
 
DSCSA. Yeah.
 
That rollout. And honestly, all the ongoing exception handling we are still seeing, it just consumed massive amounts of time, capital, and organizational energy. So people are just tired.
 
You want to break.
 
Yeah, but as our source material highlights, there is no rest period. A new massive transition is basically already taking its place. If you look at recent industry gatherings like the Healthcare Distribution Alliance traceability seminar, discussions that were supposed to be completely about DSCSA exception handling just kept pivoting back to NDC twelve.
 
Wow. So it's just hijacking the agenda.
 
Pretty much. The industry is really starting to wake up to the sheer scale of what's coming.
 
Okay, let's unpack this. We need to shift away from that regulatory fatigue for a second and just look at the undeniable math that is actually forcing the FDA's hand here.
 
The math is really the core of the whole issue.
 
Because on March 7, 2033, the FDA is officially transitioning to a uniform 12-digit format for the National Drug Code. They'll assign new 12-digit NDCs and convert all the old 10-digit ones to this new format.
 
And the agency has been incredibly clear about this. Do not expect this deadline to move.
 
Yeah, zero extensions coming. And the fundamental reason they refuse to move that date isn't just bureaucratic stubbornness. It really just comes down to simple arithmetic.
 
That's right. The FDA is simply running out of 10-digit codes.
 
Which sounds so basic, right?
 
It does, but the math of depletion here is actually pretty stark. Kayla Schenkel, who is the VP of regulatory affairs at the Healthcare Distribution Alliance, she actually broke down the exact numbers that the FDA shared.
 
And what do those look like?
 
The pharmaceutical industry currently burns through about 1,000 NDCs a year.
 
Okay.
 
And the most recent estimates show that there are only about 10,000 NDCs left in the current 10-digit format.
 
Oh wow. So you don't even need a calculator for that.
 
Exactly. When you divide that remaining inventory by the annual consumption rate, you just hit a hard mathematical wall. That finite capacity is exactly why a specific non-negotiable runway is enumerated in the final rule.
 
They physically can't delay it.
 
The FDA literally cannot extend the timeline because the entire numbering system will just collapse.
 
And the thing is, that annual consumption rate of 1,000 codes, that isn't even a guaranteed maximum. It is incredibly vulnerable to unpredictable market spirals. Oh, totally. Our source material points out that the pandemic provided this perfect real-world stress test of the numbering system. During COVID-19, the industry burned through an astonishing 6,000 to 7,000 NDCs incredibly fast.
 
Yeah, that hand sanitizer boom is the perfect example of why those long-term capacity projections can just vanish overnight.
 
Because everybody started making it.
 
Exactly. Suddenly you had cosmetic brands, local distilleries, entirely new manufacturing entities producing hand sanitizer, and every new manufacturer required a labeler code.
 
And every size, right?
 
Yes. Every new bottle size, from a tiny travel bottle to a massive industrial jug, required a unique identifier. Even a slight change of the formulation meant you needed a new code.
 
That is wild.
 
It completely changed how regulatory bodies view that numbering runway. A sudden influx of products accelerates the consumption so dramatically that honestly you can no longer trust a basic 10-year projection.
 
It's essentially the pharmaceutical equivalent of the telecommunications industry running out of area codes in the 90s.
 
Oh, that's a really good comparison.
 
When cell phones and pagers became ubiquitous, you couldn't just squeeze more phone numbers into a finite space once all the mathematical permutations were exhausted. The whole grid had to be re-architected. Or you could look at the internet running out of IPv4 addresses. Eventually you have to upgrade the core architecture to accommodate a longer string of data.
 
Exactly.
 
But here is where we need to bridge the gap for you, the listener.
 
Yeah.
 
Because while running out of numbers sounds strictly like an IT problem or like a database field issue, it actually triggers a massive physical crisis right on the packaging floor.
 
Yeah, the translation from a digital data field to a physical infrastructure challenge is where this gets highly complex. At that recent traceability seminar we mentioned, you could literally see the light bulbs going on around the room when packaging professionals realized this is not just a simple formatting update on a PDF artwork file.
 
It's not just graphic design.
 
No, it's a broad transformation affecting operational, commercial, and regulatory processes, but it lands heavily, heavy on physical hardware.
 
Okay, hold on. I actually have to push back here for a second.
 
Sure, go for it.
 
Because I'm trying to look at this from the perspective of an operations manager on the floor. We're literally talking about adding two digits to a label, just a 10 becoming a 12. Why does making a numerical string slightly longer require me to tear up my manufacturing floor, buy entirely new packaging equipment, and install brand new vision systems? It just seems like overkill.
 
What's fascinating here is that it sounds counterintuitive, but it's not about the physical space those two digits take up on a carton.
 
Okay.
 
It is entirely about data architecture, machine readability, and automated verification standards. Our source material details how moving away from traditional linear barcodes to 2D data matrix barcodes basically changes the fundamental physics of the packaging line.
 
The physics?
 
Let's say a manufacturer decides to eliminate a linear barcode that currently has the NDC and encode that information within a 2D data matrix instead just to accommodate the new 12-digit format.
 
Makes sense.
 
But when you add more data to a 2D barcode, the grid itself becomes denser. The tiny black and white squares inside that barcode become much smaller and they get packed way more tightly together.
 
So wait, if the squares are smaller, the printing technology suddenly struggles to render them sharply on the line.
 
Precisely. The thermal inkjet or laser printer that's currently sitting on your line might be perfectly capable of printing a 10-digit encoded matrix at, say, 300 cartons a minute. But when that matrix becomes denser to hold those 12 digits, the printer might smear those tiny squares just enough to degrade the quality.
 
Wow.
 
And it goes beyond printing. Barcode quality verification is a massive operational hurdle here.
 
Because the cameras have to read it.
 
A printed code that currently gets an A or B verification grade on your line right now might fail completely when the data structure changes. Simply because the hardware cannot resolve that denser image at high line speeds.
 
Which means you aren't just looking at the label artwork, you have to evaluate every single piece of hardware interacting with that label.
 
Every single piece. And she points directly to the very recent precedent set during the DSCSA serialization and aggregation implementation.
 
Oh, you mean the famous equipment rush?
 
Exactly. During that big regulatory push for DSCSA, pharmaceutical manufacturers and contract packaging organizations all basically realized at roughly the same time that they needed new high-resolution cameras. They needed new scanners, updated packaging line technology. And that simultaneous realization created massive industry-wide supply chain bottlenecks for packaging equipment. Trevor Burrus, Jr.
 
Because everyone was ordering it once.
 
Exactly. Equipment suppliers faced intense, highly concentrated demand. Lead times for just a simple inspection camera went from a few weeks to several months.
 
Or even over a year in some cases, from what I remember. Trevor Burrus, Jr.
 
Suppliers simply could not fulfill orders fast enough to meet the regulatory deadline. Trevor Burrus, Jr.
 
So Campusano is essentially warning that if you wait too long to audit your lines and determine what needs to be replaced for NDC-12, you are going to walk right into another brutal equipment rush.
 
Exactly.
 
If you wait until 2030 to realize your cameras lack the resolution for those denser 2D barcodes, you're going to be standing in a procurement queue behind every other pharmaceutical manufacturer trying to meet the exact same 2033 deadline.
 
And you will likely pay a massive premium to expedite that equipment, assuming you can even get it at all.
 
So if a simple software update actually requires ripping out the physical cameras and printers on the line, the immediate question becomes who pays for that?
 
Yeah. That's the million-dollar question.
 
Literally. I cannot imagine the finance department is just sitting on a pile of discretionary cash waiting to buy new vision systems for every single packaging line in the facility. This is where the cross-departmental chaos really starts to show itself.
 
It really does. The necessity of breaking down those departmental silos is a major theme throughout this entire analysis. And EC-12 does not belong exclusively to the packaging department, nor does it belong strictly to IT or regulatory. Libby Dewey, she's the manager of DSCSA at Cardinal Health. She emphasizes that no single organization controls this entire transition.
 
It's everyone's problem.
 
Yeah. Internally, it cannot be managed on a silo-by-silo basis.
 
Aaron Powell You can see exactly how the workflow breaks if these departments don't talk. Regulatory affairs knows the FDA's rule and they know the legal deadlines, but they don't buy equipment. The IT department sees NDC 12 primarily as a database field change. So they're focused on server architecture and data storage, not the physical cartons on the floor.
 
Exactly.
 
The packaging engineers are terrified about line speeds, printer resolution, and camera inspection failures. Meanwhile, the finance department is just looking at the capital requirements and trying to protect the quarterly budget.
 
Yep.
 
If one link in that internal workflow fails, the product cannot ship.
 
And the financial reality is that this transition will not occur in a vacuum. Over the next seven years, manufacturers will simultaneously be upgrading production lines, replacing aging legacy equipment, launching new products.
 
They do everything they normally do.
 
Pursuing other digital transformation projects. Operations cannot just halt all other business initiatives to fund new barcode scanners. So to manage this reality, Kempasano offers a highly effective financial strategy for the packaging professional, which is kiggybacking.
 
I love this concept because it gives you, the listener, a direct, actionable way to talk to your chief financial officer today.
 
Yeah, it's essentially a strategy of collaborative capital expenditure. NDC 12 upgrades should not compete for budget against other critical operational initiative. Okay. They need to be seamlessly integrated into them. So if you know that your organization needs to replace a packaging line control platform or maybe upgrade an enterprise resource planning system before 2033, you must write the NDC 12 requirements into the specification for that investment right now.
 
Let's give a concrete example of how a listener can actually apply that. So say you are budgeting for a new blister packaging line that is scheduled to be installed in 2027.
 
Okay, perfect example.
 
The request for proposal, the RFP, going out to vendors today, must explicitly state that all printers, cameras, and software on that new line must natively handle 12-digit NDCs and dense 2D data matrix parsing. If you do not piggyback those requirements onto the 2027 project, you will spend millions on a new blister line, only to have to rip out its software and vision systems five years later to meet the 2033 mandate.
 
Exactly. Writing those specifications today prevents buying equipment that is mathematically guaranteed to be obsolete tomorrow. Yeah. By looking for opportunities to combine projects, you reduce duplicate engineering work and you protect the company from unexpected secondary upgrade costs.
 
Which finance will love.
 
Oh, absolutely. But securing the capital budget and fixing the physical machinery is still only part of the puzzle here. There is a massive operational trap waiting regarding the physical inventory itself.
 
Okay, yeah. This connects the timeline of implementation directly to the physical shelf life of pharmaceutical products. Because fixing the machines is one thing, but what about the physical boxes sitting in a warehouse or on a pharmacy shelf? Let's outline the redway clearly for everyone. The official transition period runs from March 5, 2026 to March 6, 2033. However, there is a critical intermediate milestone.
 
The 2030 testing phase.
 
Exactly. The general understanding across the supply chain is that comprehensive system testing across multiple trading partners needs to begin by 2030. Industry leaders want three solid years of interoperability testing before the hard cutoff.
 
Now, this raises an important question concerning physical packaging inventory and legacy products. Okay. What happens to products that have unusually long shelf lives? Manufacturers have to work backward from the 2033 transition date to determine exactly when labels and printed packaging carrying the existing 10-digit NDC format should permanently stop entering production.
 
Let's run the math on that for a second. If you manufacture a bottle of tablets in 2029 and that product has a five-year shelf life, it doesn't expire until 2034, but it has an NDC 10 label printed on the bottle. That means the product will still be circulating in the physical supply chain when the uniform 12-digit rule takes effect in 2033.
 
And that scenario is exactly what Rose Campusano is warning about. She's asking companies to seriously evaluate their demand planning and labeling strategies right now.
 
Because if you don't calculate shelf life into your transition plan, you will literally get caught with physical inventory carrying an obsolete NDC tin.
 
Exactly. Excess legacy inventory could leave manufacturers facing massive relabeling efforts at the warehouse level.
 
Which is incredibly expensive.
 
Or expensive product rework, or simply having to write off huge amounts of obsolete packaging materials and finished goods.
 
Yeah. Packaging, regulatory, supply chain, and production teams. They must map out exactly how legacy products move through their specific distribution channels.
 
Yes.
 
You have to calculate how long existing inventory typically remains in the marketplace so you can effectively drain the system of 10-digit physical labels before the clock runs out.
 
But here is where we run into the most challenging regulatory constraint of this entire process.
 
Oh boy.
 
You might hear all of this regarding shelf life and equipment upgrades and think, okay, the safest route is to just upgrade everything immediately and start printing 12-digit NDCs on our commercial boxes next year.
 
Get ahead of the curve, avoid the rush entirely.
 
You cannot do that.
 
Wait, really?
 
No. Libby Dewey issues a stark warning drawn directly from the FDA's guidance. You absolutely cannot get ahead of the transition on commercial packaging. Oh wow. Here's where it gets really interesting. If a product hits the market with an NDC 12 physical label prior to the effective date in 2033, the FDA considers it a misbranded product.
 
Let that sink in. The FDA will literally consider your product misbranded and subject to regulatory action if you implement the required 12-digit label too early.
 
Yes.
 
Just as they will take action against the 10-digit format if it is introduced into commerce after the switch. That is wild.
 
The implications for operations are staggering. It creates a razor-thin margin of error for demand planning and supply chain teams.
 
I can imagine.
 
You have a multi-year window to upgrade all your internal software, replace your packaging line cameras, validate new printers, and test your data exchanges with trading partners in a sandbox environment. But you cannot actually flip the switch on the physical printed label entering the commercial market until the exact right moment.
 
It is the ultimate catch-22 for a packaging professional. You must be fully capable of printing, scanning, and distributing the 12-digit code years in advance to participate in industry testing.
 
Yep.
 
But you are legally prohibited from putting it on a commercial product until the FDA's effective date.
 
Exactly.
 
It requires an extraordinary level of synchronized orchestration across your entire company. You are essentially building a brand new airplane while flying the old one, and you have to swap them mid-air at a highly specific time.
 
That's a great way to put it. This catch-22 emphasizes why the consistent message from the FDA, from the Healthcare Distribution Alliance, and all these industry speakers is straightforward. Start mapping now.
 
Today.
 
You have to understand your own environment completely before you can orchestrate a cutover of that magnitude. You need to uncover every single hidden operational trap where systems make assumptions about the existing NDC structure.
 
So to help you avoid those traps, let's run through a practical FDA-backed framework provided by Libby Dewey at the Traceability Seminar.
 
This is really useful.
 
Yeah. And instead of just reading a checklist, let's look at how these steps expose the actual vulnerabilities in your workflow.
 
Okay.
 
Step one is identifying everywhere the NDC lives in your company. And the trap here is only looking at the printed carton.
 
Oh, because it's everywhere.
 
Exactly. You have to look at labeling systems, artwork files, enterprise resource planning software, financial systems, warehouse management databases, and the actual programmable logic controllers on the production equipment.
 
And the second major trap involves how your legacy systems handle data translation. You have to check your systems and assess their readiness to accept both formats during that transition window. A critical technical detail here, and perhaps the most common trap companies are finding, is the leading zero problem.
 
Ah, the leading zero, where the legacy software sees a zero at the front of a code, assumes it has no mathematical value, and just deletes it.
 
Exactly. In standard arithmetic, a zero at the front of a number doesn't change the value, but in a national drug code, that zero is a critical identifier.
 
It's part of the string.
 
If your legacy database drops the leading zero, the string is fundamentally broken and your product effectively disappears from the traceability system. Furthermore, you must verify that your systems can read the denser 2D barcodes with your current hardware and successfully parse that data into your software architecture without dropping characters.
 
Okay, so another major vulnerability is how systems currently drive their data. Many packaging and warehouse systems right now, they take the longer Globe identifier, the global trade item number, or GTIN, and they use a hard-coded shortcut formula to extract the 10-digit NDC out of it. The software basically says skip the first few digits of the GTIN, grab the next 10, and that is your NDC.
 
And if you bump that NDC to 12 digits, that extraction logic completely breaks down.
 
It just pulls the wrong numbers.
 
Yeah, the shortcut formula starts pulling the wrong string of numbers, which might include packaging indexes or check digits instead of the actual drug code. So if your current systems are driving the NDC out of the GTIN, you must revisit and rewrite that logic entirely.
 
Got it. And finally, you have to clean up your master data immediately. Auditor operations to assess exactly where you are handing off NDCs to trading partners.
 
Yes, because if you don't clean up the master data now, you literally cannot successfully participate in the industry-wide interoperability testing targeted for 2030.
 
Which is only a few years away.
 
Exactly. Addressing those operational traps forms the foundation of a successful transition plan. And while the FDA's mathematical mandate is the undeniable catalyst forcing this massive technological overhaul, it actually leaves us with a highly provocative implication to consider.
 
Oh, what's that?
 
This forced upgrade, as disruptive and capital-intensive as it is, might actually be the catalyst that finally pushes the pharmaceutical packaging industry to unify its deeply isolated data systems.
 
Oh, interesting. So it's like a forcing function for good.
 
Precisely. By surviving the intense scrutiny, the cross-departmental collaboration, and the system mapping required for the NDC-12 transition, packaging lines and enterprise databases might inadvertently become fully future-proofed.
 
This makes total sense. Because the required effort forces the industry to build a much better, more robust digital highway rather than just changing the numbers on the license plate. Exactly. The math of depletion is forcing your hand, much like the telecommunications industry running out of area codes. The physical vision equipment on your packaging floor, the capital budgets in your finance department, and the long-term sharp life planning of your supply chain all hinge on how you respond to the addition of those two little digits.
 
It's all connected.
 
The deadline is 2033, and it is a hard stop. Thank you for joining this deep dive. Start mapping your systems today, evaluate your packaging hardware, talk to your finance department about piggybacking those upgrades, and ensure your operations do not get caught without a runway.
 
Thank you for listening to Through the Line Packaging and Processing. You can listen to more episodes on all streaming platforms. Be sure to visit us at packworld.com, profoodworld.com, and healthcarepackaging.com for more packaging and processing news. This podcast was edited by Bri Guntz.